Immix Biopharma, Inc. (IMMX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on May 22, 2026. Immix Biopharma, Inc., a Delaware corporation and emerging growth company, is headquartered in Los Angeles, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "IMMX."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Directors - All nine director nominees were elected. The voting results were as follows:
| Director Nominee | For Votes | Withheld Votes | Broker Non-Votes |
|---|---|---|---|
| Ilya Rachman | 35,738,887 | 121,893 | 6,445,684 |
| Gabriel Morris | 34,353,302 | 1,507,479 | 6,445,683 |
| Jason Hsu | 35,844,812 | 15,969 | 6,445,683 |
| Magda Marquet | 35,731,188 | 129,592 | 6,445,684 |
| Helen C. Adams | 35,677,258 | 183,522 | 6,445,684 |
| Carey Ng | 35,840,860 | 19,921 | 6,445,683 |
| Jane Buchan | 35,731,346 | 129,434 | 6,445,684 |
| Yekaterina Chudnovsky | 35,749,420 | 111,360 | 6,445,684 |
| Nancy Chang | 35,744,455 | 116,325 | 6,445,684 |
- Proposal 2: Ratification of Auditors - Stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm for the year ending December 31, 2026.
| Vote Type | Count |
|---|---|
| For | 42,276,496 |
| Against | 11,526 |
| Abstentions | 18,442 |
| Broker Non-Votes | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of votes cast "For" each director to assess shareholder support levels.
- Confirm the specific terms of the engagement with Crowe LLP as the independent auditor for the 2026 fiscal year.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 6, 2026, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Note the significant number of broker non-votes (approx. 6.4 million) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting authority.